Bypassing the Jiangsu Securities and Regulatory Bureau Nanjing Medicine was directly filed by the SFC

Han Xun The new chairman of the sixth month, Nanjing Medicine (600713.SH) was filed for investigation.　　September 23, Nanjing Medical issued a notice, because of the alleged failure to disclose information, Nanjing Medicine by the CSRC to investigate.　　According to the reporter understanding of the situation, the Nanjing Medical Commission is not the case of the investigation from individual reports, but the SFC in the company before the disclosure of information violations of things to investigate.　　In the past two years, this newspaper has carried on the detailed report to the Nanjing Medicine repeatedly equity transfer. Or to deal with different opinions "The CSRC investigation is directly implemented, Jiangsu Bureau is not involved in this side."　　"September 23, the reporter in the identity of investors to consult the Jiangsu Securities Regulatory Bureau listed companies supervision of a place, said a staff member.　　For Nanjing Medicine "because of the alleged failure to disclose" the "information", the above-mentioned staff said that the scope of the understanding is relatively large, "such as information disclosure of the authenticity and so on, specific to the Nanjing Medical Bulletin, because it involves the reasons for our work, some things can not say more."　　The reporter then consulted Nanjing medicine, a staff member told reporters that the alleged disclosure of information violations and the recent replacement of the Chairman, the president has no relationship, "there is no investigation team and related personnel to put forward further cooperation requirements."　　However, the staff told reporters that he personally believes that the case is mainly about the company before the disclosure of information violations, "already have public information disclosed."　　Review of Nanjing Pharmaceutical calendar year notice, only this April or May has been the Jiangsu Securities Regulatory Bureau ordered corrective measures announced. May 3, 2013, Nanjing Pharmaceutical issued "on the receipt of Jiangsu Securities Regulatory Bureau Administrative Supervision Measures decision book" announcement, April 28, the company received Jiangsu Securities Bureau issued the "on the Nanjing Pharmaceutical Co., Ltd. to take orders to rectify the decision", the decision book pointed out that Nanjing Pharmaceutical information disclosure violations, There are three major issues of non-compliance with the decision-making process and the inability of the board to be diligent and responsible. The three major issues are: 2011 The company in the transfer of Nanjing Securities [micro-BO] and Nanjing Tong Ren Tong Pharmaceutical industry, such as 6 subsidiaries in the process of the relevant important board resolution did not timely implementation of information disclosure obligations; December 29, 2011, The company commissioned the South Medicine International acquisition of Yancheng Heng Health Equity issues constitute related transactions should be submitted to the general meeting of shareholders to perform the examination and approval process, and the company did not perform the general meeting of the approval process of shareholders to carry out transactions, after the implementation of the general meeting of shareholders in the approval process.　　The board failed to be diligent and conscientious in the consideration of the transfer of stock rights in Nanjing, the abandonment of the South Medicine international priority, and the Commission of the South Medicine International acquisition of Yancheng Heng Jian Equity. At the same time, Jiangsu Securities and Regulatory Bureau requires Nanjing medicine to disclose truthfully the 2011 transfer of the stock market of Nanjing Securities and 6 subsidiaries of the real situation and requirements of the company's original chairman Zhou Yaoping, director and President He Jinxian, Vice Chairman Liang Yutang, director Wang Yao, directorYang Jinping, director of Ding, independent director Gu Weijun, independent director Shangyang, independent director of the quarterly articles, Dong Secretary Shang on May 15, 2013 to Jiangsu Securities Regulatory Bureau to accept the supervision of the talks.　　Today, Zhou Yaoping, He Jinxian, Wang Yao, Yang Jinping and Ding are no longer serving in Nanjing Medicine.　　A source told reporters that the China Securities Regulatory Commission to investigate the case should be aimed at the three major issues, "Jiangsu Bureau was only issued corrective measures, and the meeting has different views, and finally decided to file an investigation."　　Had kangaroo the money in addition, the above sources also told reporters that the SFC is not ruled out investigation is aimed at Nanjing medicine has been the Ministry of Finance of China's accounting information quality inspection found problems.　　In 2009, the Ministry of Finance organized the Office of the Financial Ombudsman in various places (hereinafter referred to as the Commissioner office) to check the quality of accounting information of 78 enterprises and the practice quality of 43 CPA firms.　　Among them, the Ministry of Finance in Jiangsu Province, the office of the Financial Ombudsman of Nanjing Pharmaceutical 2008 Annual Accounting information Quality inspection. Inspection found that Nanjing Pharmaceutical import and Export branch of the export agency less than 1.39 million yuan income fee; Nanjing Tongren Tong Pharmaceutical Co., Ltd. (hereinafter referred to as Nanjing Tang Ren Tang) to the company and individual employees to open a settlement, the formation of 6.64 million yuan external funds, mainly for the issuance of company personnel bonuses; Nanjing Fun Medicine Co., Ltd. ( Under the "Fun Medicine" through the virtual listed advertising fees, conference fees, labor costs to cash and interception of consignment, the formation of 6.63 million yuan outside the fund, mainly for the issue of corporate bonuses and other issues.　　In view of the inspection findings, the Ministry of Finance in Jiangsu Province, the office of the Financial Ombudsman has been dealt with according to law.　　But the Nanjing medicine will come to this situation today, perhaps the union Bo posture completely did not think of. According to the Nanjing Medicine 2013.5 Annual Report, "reporting period company and joint Bo Posture Strategic cooperation project made substantial progress." The company is legally compliant to divest foreign companies from entering the industry assets, and to obtain the Nanjing Investment Promotion Committee and Jiangsu Province Business Department agreed to transfer the letter. July 12, the company will formally submit the project declaration to the Ministry of Commerce, marking the project has entered the national level approval process. Other work companies and joint Bo posture also continued to promote.　　"For the current case of Nanjing Medical Investigation on the impact of joint Bo posture Cooperation, the Nanjing medical staff told reporters that the investigation of the joint Bo posture reorganization is a good thing."　　However, from the past practice, if the letter of Nanjing Medicine to wear a serious violation, painstakingly built up years of cooperation with Nanjing Pharmaceutical joint Bo posture or hard to make any substantial progress.　　In addition, Nanjing medicine over the years has been criticized by the market is its tens of billions of revenue to change the pattern of loss, so that investors can not be. Data show that Nanjing Pharmaceutical main pharmaceutical circulation, the first half of 2013 to achieve operating income of 9.202 billion yuan, but nearly billion revenue for shareholders to create a net profit of 16.39 million yuan, if deducted from the sale of assets of 25.07 million yuan, the first half of the company operating business losses of about 8 million yuan。 "Pharmaceutical circulation industry gross profit margin of 5%-6%, net interest rate of 1%, the normal situation of tens of billions of dollars should be net profit of about 100 million yuan, Nanjing medicine this situation is abnormal."　　"said a researcher on the drug industry, a brokerage who declined to disclose his identity.　　In addition, the reporter looked at the pharmaceutical circulation of comparable companies in the same (000028.SZ), its first half of the pharmaceutical circulation operating income of 9.19 billion yuan, pharmaceutical manufacturing revenue of 870 million yuan, the first half to achieve net profit of 270 million yuan. The reporter reads the Nanjing medicine financial statement to discover, the Nanjing Medicine has the massive correlation transaction, only in the first half with the brothers Company and the subsidiary's related transaction to reach 830 million yuan, moreover also has the massive and the related person's creditor debt relations.　　"The more associated transactions, the lower the company's financial transparency, the greater the company's financial footprint," a senior financial person told reporters.　　For the letter to cover the violation of the case when the investigation can be concluded, the Jiangsu Securities and Supervision Bureau staff Frankly, this is hard to say. Indeed, in March 2012, the China Securities Regulatory Commission to investigate the South spinning shares (600250.SH) has no any thereafter, the researcher bluntly Nanjing Medical investigation results at least until next year or will be a bit.